Doctor's Guide report on the FDA approval of the recombinant tissue plasminogen activator (t-PA) includes clinical study results.
Kaiser Permanente clinical practice guidelines outline the indications and contraindications for tissue plasminogen activator therapy.
US prescribing information for this medication used to treat heart attacks, acute ischemic stroke, and acute, massive pulmonary embolism.
Press release saying eight out of ten physicians would choose Activase for therapy if they, themselves, were having a heart attack.
Explore the indications, mechanism of action, dosage, and side effects of the fibrinolytic agent, also known as tPA, Activase, and Alteplase.
Study found treatment with tissue plasminogen activator was more costly than streptokinase, but offered higher patient survival rates.